AddLife AB (ALIF.B) AI Stock Analysis

• Market Cap: $22.79B
• Dividend Yield: 0.4%
• Average Volume (3M): 97.37K
• Price to Earnings (P/E): 57.8
• Beta (1Y): 0.67
• Revenue Growth: 5.14%
• EPS Growth: 236.75%
• Country: SE
• Employees: 2,251
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.29
• Shares Outstanding: 117,877,460
• 10 Day Avg. Volume: 108,367
• 30 Day Avg. Volume: 97,373
• PEG Ratio: 2.03
• Price to Book (P/B): 3.15
• Price to Sales (P/S): 1.63
• P/FCF Ratio: 20.97
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 2.50
• Enterprise Value/Gross Profit: 6.62
• Enterprise Value/Ebitda: 25.63
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 6.48
• Revenue Forecast (FY): $10.52B

• Rating: 64 Neutral
• Price Target: kr200.00 ▲(11.17% Upside)

AddLife AB's strong financial performance, characterized by revenue growth and operational efficiency, is a key strength. However, the high P/E ratio and low dividend yield suggest valuation concerns. Technical indicators show neutral market sentiment, contributing to a moderate overall stock score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for AddLife's products and services, supporting long-term business expansion and market penetration.

Operational Efficiency

Stable gross margins reflect effective cost control, which enhances profitability and provides a competitive edge in the life sciences sector.

Cash Generation

High cash generation relative to net income ensures liquidity for operations and potential investments, supporting sustainable growth.

Negative Factors

Profitability Concerns

Low net profit margins may limit reinvestment capabilities and shareholder returns, potentially affecting long-term financial health.

Free Cash Flow Growth

Stagnant free cash flow growth could hinder the company's ability to fund new projects and respond to market opportunities, impacting future expansion.

Equity Ratio Concerns

A moderate equity ratio indicates a balanced asset structure, but rising debt could strain financial stability and increase risk exposure.

AddLife AB Business Overview & Revenue Model

Company Description

AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.

How the Company Makes Money

AddLife AB generates revenue through multiple streams, primarily focusing on the sale of medical and laboratory products. The company's revenue model is driven by its distribution business, which involves sourcing products from various manufacturers and selling them to healthcare facilities, laboratories, and research institutions. Key revenue streams include direct sales of medical devices, laboratory equipment, and consumables, as well as service agreements and maintenance contracts. Additionally, AddLife benefits from strategic partnerships with leading manufacturers, which enhance its product offerings and market reach. The company also invests in value-added services such as training and support, which contribute to customer loyalty and recurring revenue. Overall, AddLife's diverse product portfolio and strong industry relationships are critical factors that bolster its financial performance.

AddLife AB Financial Statement Overview

Summary

AddLife AB shows strong revenue growth and operational efficiency with stable gross margins. The balance sheet reflects prudent debt management, but there is room for improvement in profitability and cash flow growth.

Income Statement

AddLife AB has demonstrated consistent revenue growth, with a notable increase of 81.4% in the TTM period. The gross profit margin remains stable around 37.8%, indicating efficient cost management. However, the net profit margin is relatively low at 3.2%, suggesting room for improvement in profitability. The EBIT and EBITDA margins have shown slight improvements, reflecting operational efficiency gains.

Balance Sheet

The company's debt-to-equity ratio has improved slightly to 0.96, indicating a balanced approach to leveraging. Return on equity has increased to 6.5% in the TTM period, showing better utilization of equity. However, the equity ratio remains moderate, suggesting a balanced asset structure but with potential risks if debt levels increase.

Cash Flow

Operating cash flow has shown a steady increase, supporting the company's operations effectively. The free cash flow to net income ratio is strong at 95.7%, indicating good cash generation relative to net income. However, free cash flow growth has stagnated, highlighting potential challenges in expanding cash reserves.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.53B	10.29B	9.69B	9.08B	7.99B	5.27B
Gross Profit	3.98B	3.86B	3.60B	3.43B	2.86B	1.82B
EBITDA	1.03B	1.52B	1.53B	1.45B	1.46B	951.00M
Net Income	394.00M	252.00M	190.00M	480.00M	719.00M	517.80M
Balance Sheet
Total Assets	12.66B	13.05B	12.74B	13.06B	10.60B	4.15B
Cash, Cash Equivalents and Short-Term Investments	286.00M	331.00M	272.00M	376.00M	345.30M	216.00M
Total Debt	5.02B	5.07B	5.29B	5.59B	4.10B	805.80M
Total Liabilities	7.35B	7.75B	7.79B	8.09B	6.30B	2.26B
Stockholders Equity	5.30B	5.31B	4.96B	4.97B	4.29B	1.88B
Cash Flow
Free Cash Flow	1.11B	798.00M	465.00M	627.00M	866.30M	857.90M
Operating Cash Flow	1.17B	1.09B	773.00M	909.00M	1.01B	950.10M
Investing Cash Flow	-511.00M	-386.00M	-317.00M	-1.09B	-2.98B	-428.70M
Financing Cash Flow	-591.00M	-682.00M	-554.00M	134.00M	2.07B	-372.50M

AddLife AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 179.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Negative. The current price of 179.9 is below the 20-day moving average (MA) of 184.21, below the 50-day MA of 187.09, and above the 200-day MA of 175.94, indicating a neutral trend. The MACD of -1.48 indicates Positive momentum. The RSI at 39.70 is Neutral, neither overbought nor oversold. The STOCH value of 49.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ALIF.B.

AddLife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VITR	71 Outperform	kr18.98B	43.02	3.34%	0.75%	-1.29%	―
BONEX	66 Neutral	$12.79B	84.18	19.59%	―	37.41%	67.03%
ALIF.B	64 Neutral	$22.79B	57.81	7.24%	0.40%	5.14%	236.75%
VIMIAN	64 Neutral	€15.69B	44.40	4.63%	―	17.13%	―
EKTA.B	55 Neutral	kr17.77B	64.87	3.08%	4.30%	-0.90%	-70.95%
PAX	52 Neutral	$1.54B	138.75	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

AddLife AB Corporate Events

AddLife AB Reports Strong Growth and Earnings

AddLife AB Class B is a prominent player in the life sciences sector, specializing in providing advanced products and services in the Labtech and Medtech markets across Europe. The company’s recent earnings report highlights a strong quarter with significant organic growth and improved margins, reflecting its strategic focus on efficiency and product portfolio enhancement. Key financial metrics include a 4% increase in net sales to SEK 2,429 million and a notable 17% rise in EBITA to SEK 270 million, driven by a 6% organic growth rate. The company’s profit after tax surged by 228% to SEK 82 million, and earnings per share increased to SEK 0.66. The acquisition of Edge Medical Ltd. is expected to further bolster annual net sales by approximately SEK 90 million. Looking ahead, AddLife’s management remains optimistic about continued growth and profitability improvements, supported by its strong market position and strategic initiatives in high-margin niches.

AddLife AB Reports Strong Q3 2025 Performance and Strategic Acquisition

AddLife AB reported strong financial performance for the third quarter of 2025, with a 4% increase in net sales and a significant 228% rise in profit after tax. The company also completed the acquisition of Edge Medical Ltd., which is expected to boost annual sales by SEK 90m, further strengthening its market position.

The most recent analyst rating on ($SE:ALIF.B) stock is a Hold with a SEK195.00 price target. To see the full list of analyst forecasts on AddLife AB stock, see the SE:ALIF.B Stock Forecast page.